HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol. METHODS: A post hoc analysis of the recently completed Treating to New Targets (TNT) study assessed the predictive value of HDL cholesterol levels in 9770 patients. The primary outcome measure was the time to a first major cardiovascular event, defined as death from coronary heart disease, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The predictive relationship between HDL cholesterol levels at the third month of treatment with statins and the time to the first major cardiovascular event was assessed in univariate and multivariate analyses and was also assessed for specific LDL cholesterol strata, including subjects with LDL cholesterol levels below 70 mg per deciliter (1.8 mmol per liter). RESULTS: The HDL cholesterol level in patients receiving statins was predictive of major cardiovascular events across the TNT study cohort, both when HDL cholesterol was considered as a continuous variable and when subjects were stratified according to quintiles of HDL cholesterol level. When the analysis was stratified according to LDL cholesterol level in patients receiving statins, the relationship between HDL cholesterol level and major cardiovascular events was of borderline significance (P=0.05). Even among study subjects with LDL cholesterol levels below 70 mg per deciliter, those in the highest quintile of HDL cholesterol level were at less risk for major cardiovascular events than those in the lowest quintile (P=0.03). CONCLUSIONS: In this post hoc analysis, HDL cholesterol levels were predictive of major cardiovascular events in patients treated with statins. This relationship was also observed among patients with LDL cholesterol levels below 70 mg per deciliter. (ClinicalTrials.gov number, NCT00327691 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that HDL cholesterol (HDL-C) levels under statin treatment remain an independent predictor of the risk of cardiovascular events in patients who have been treated with statins to lower LDL-C levels4”
From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice (2012) · cites this paper as [4]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.151”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [151]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [292]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- 10.1001/jama.251.3.351 · DOI · Paper page
Cited by
Items 801–900 of 1,001
Novel Size‐Based High‐Density Lipoprotein Subspecies and Incident Vascular Events
Deets, A., Joshi, P. H., Chandra, A., Singh, K., Khera, A., Virani, S. S., Ballantyne, C. M., Otvos, J. D., Dullaart, R. P. F., Gruppen, E. G., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031160 · Cited by 13
Dyslipidemia and Cardiovascular Disease
Fakhrzadeh, H., & Tabatabaei‐Malazy, O. (2012) · InTech eBooks · doi:10.5772/30009 · Cited by 19
Robinson, J. G. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3190 · Cited by 14
“While levels of HDL-C and triglycerides remain predictive of cardiovascular risk in patients with LDL-C levels at goal, it is not entirely clear whether the HDL-C increases or triglyceride decreases from drug therapy contribute substantial additional benefi t beyond that expected from LDL-C lowering.(36,59) An evidenc…”
High-density lipoprotein: A fall from grace?
van Leuven, S. I., Stroes, E. S. G., & Kastelein, J. J. P. (2008) · Annals of Medicine · doi:10.1080/07853890802082104 · Cited by 13
Self-citationImportant Considerations for Treatment with Dietary Supplement versus Prescription Niacin Products
Backes, J. M., Padley, R. J., & Moriarty, P. M. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.03.2265 · Cited by 14
Ohnsorg, P. M., Mary, J.-L., Rohrer, L., Pech, M., Fingerle, J., & von Eckardstein, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.001 · Cited by 15
Elevando el colesterol HDL: ¿Cuál es la mejor estrategia?
Feliciano-Alfonso, J. E., & Ariza, I. D. S. (2008) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302008000400025 · Cited by 26
Ersoy, A. Ö., Tokmak, A., Özler, S., Öztaş, E., Ersoy, E., Çelik, H. T., Erdamar, H., & Yılmaz, N. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-016-4096-8 · Cited by 14
Serum inhibitory factor 1, high-density lipoprotein and cardiovascular diseases
Martinez, L. O., Genoux, A., Ferrières, J., Duparc, T., & Perret, B. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000434 · Cited by 13
Pre- and Post-operative comparative analysis of serum lipid profile in patients with cholelithiasis
Gupta, K., & Gill, G. S. (2017) · International Journal of Applied and Basic Medical Research · doi:10.4103/2229-516x.212968 · Cited by 15
Matsumoto, I., Misaki, A., Kurozumi, M., Nanba, T., & Takagi, Y. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.07.012 · Cited by 12
Dergunova, L. V., Nosova, E. V., Dmitrieva, V. G., Rozhkova, A. V., Bazaeva, E. V., Limborska, S. A., & Dergunov, A. D. (2019) · Journal of Medical Biochemistry · doi:10.2478/jomb-2019-0052 · Cited by 13
“The existence of only two nodes may correspond to J Med Biochem 2020; 39 (3) 381”
BackgroundHoriuchi, Y., Lai, S.-J., Kameda, T., Tozuka, M., & Ohkawa, R. (2020) · Bioscience Reports · doi:10.1042/bsr20201495 · Cited by 14
Sanz, J., Moreno, P., & Fuster, V. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.018 · Cited by 19
Jekyll and Hyde of HDL: a lipoprotein with a split personality
Shah, P. K. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht382 · Cited by 15
Arutyunov, G. P., Boytsov, S. A., Voevoda, M. I., Drapkina, O. M., Kukharchuk, V. V., Ai, M., Shestakova, M. V., Gurevich, V. S., Сергиенко, И. В., Alieva, A. S., et al. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-9-44-51 · Cited by 14
Wong, T. L., Kong, Y., & Ma, S. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000837 · Cited by 19
“[155] An increased level of non-HDL-C was also frequently observed in NASH patients.”
Hypothyroidism and the risk of coronary artery disease in Saudi patients
Mahzari, M. M., Alserehi, A. H., Almutairi, S., Alanazi, K. H., Alharbi, M., & Mohamud, M. (2022) · Journal of Family and Community Medicine · doi:10.4103/jfcm.jfcm_368_21 · Cited by 17
HDL: To Treat or Not To Treat?
Pirillo, A., Tibolla, G., Norata, G. D., & Catapano, A. L. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0429-x · Cited by 12
Use of Expert Consensus to Improve Atherogenic Dyslipidemia Management
Núñez-Cortés, J. M., Pedro‐Botet, J., Brea-Hernando, Á., Rodríguez, Á. D., González‐Santos, P., Hernández‐Mijares, A., Mantilla, T., Pintó, X., & Simó, R. (2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.06.011 · Cited by 13
Ishida, M., Itoh, T., Nakajima, S., Ishikawa, Y., Shimoda, Y., Kimura, T., Fusazaki, T., & Morino, Y. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0264-17 · Cited by 13
Ajabnoor, G., Bahijri, S., Alamoudi, A. A., Al-Raddadi, R. M., Al-Ahmadi, J., Jambi, H., Borai, A., & Toumilehto, J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246568 · Cited by 15
Sun, S., Kong, Z., Shi, Q., Zhang, H., Lei, O.-K., & Nie, J. (2021) · Healthcare · doi:10.3390/healthcare9060637 · Cited by 14
Pan, S.-Y., Zhu, P., Zhou, S., Zhang, Y., Wang, X., Sun, N., Chu, Z.-S., Yu, Z., & Ko, K. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s73544 · Cited by 13
Toth, P. P. (2010) · Current Cardiology Reports · doi:10.1007/s11886-010-0136-3 · Cited by 12
“Further accentuating the need to more effectively address the problem of low HDL, even among patients with LDL-C less than 70 mg/dL [17] or less than 60 mg/dL [18•], low HDL-C remains an independent predictor or risk for cardiovascular events.”
Guo, T., Yin, R., Lin, Q.-Z., Wu, J., Shen, S.-W., SUN, J.-Q., Shi, G.-Y., Wu, J., Li, H., & Wang, Y. (2014) · Bioscience Reports · doi:10.1042/bsr20130131 · Cited by 13
Lukšienė, D., Tamošiūnas, A., Bacevičienė, M., Radišauskas, R., Malinauskiene, V. A., Peasey, A., & Bobák, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100158 · Cited by 18
Oyewole, O. I., Shoremi, M. O., & Oladele, J. O. (2016) · American Journal of Biomedical Research · doi:10.12691/ajbr-4-2-2 · Cited by 12
CANHEART: Is HDL cholesterol a cardiovascular specific risk factor?
Hassan, M. S., & Philip, P. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2016.34 · Cited by 13
van Meijeren, A. R., Ties, D., de Koning, M.-S. L. Y., van Dijk, R., van Blokland, I. V., Veloz, P. L., van Woerden, G., Vliegenthart, R., Pundziūtė, G., Westenbrink, B. D., et al. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101006 · Cited by 13
Jameson, K., Amber, V., D’Oca, K., Mills, D., Giles, A., & Ambegaonkar, B. M. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12238 · Cited by 14
Dorais, M., Chirovsky, D. R., Ambegaonkar, B. M., Sazonov, V., Davies, G., Grant, S., & LeLorier, J. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70413-x · Cited by 14
Nogueira, J. P., Maraninchi, M., Béliard, S., Lorec, A. M., Berthet, B., Corroller, A. B., Dubois, N., Grangeot, R., Mattei, C., Gaudart, J., et al. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-17 · Cited by 13
Yu, J., Han, J., He, L., Feng, X.-H., Li, W., Mao, J., Gao, W., & Wang, G. (2013) · PubMed Central · doi:10.3969/j.issn.1671-5411.2013.02.007 · Cited by 13
Should we target HDL cholesterol level in lowering cardiovascular risk?
Toth, P. P. (2009) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.801 · Cited by 14
The evolving role of CETP inhibition: beyond HDL cholesterol
Ray, K. K., & Vallejo‐Vaz, A. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60608-0 · Cited by 11
Vlek, A. L. M., Visseren, F. L. J., Algra, A., Soedamah‐Muthu, S. S., Moll, F. L., Doevendans, P. A., Kappelle, J. L. J., van der Graaf, Y., & SMART study group (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e328336a0f8 · Cited by 11
Ascaso, J. F., Millán, J., Hernández‐Mijares, A., Blasco, M., Brea, Á., Rodríguez, Á. D., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2016.11.001 · Cited by 11
Kaur, K. K. (2015) · Journal of Health & Medical Informatics · doi:10.4172/2157-7420.1000184 · Cited by 12
Jiang, Y., Jin, M., Chen, J., Yan, J., Liu, P., Yao, M., Cai, W., & Pi, R. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172871 · Cited by 11
Biologically active components and health benefits of nettle seed oil
Petkova, Z. Y., Antova, G., & Angelova‐Romova, M. (2020) · Grasas y Aceites · doi:10.3989/gya.0108191 · Cited by 14
“0 are believed to be indicative of a better hypocholesterolemic potential of the lipids which makes them more suitable for consumption and their regular intake reduces the risk of cardiovascular disease (Barter et al., 2007).”
BackgroundInfluentialThe role of intracoronary imaging in translational research
Montarello, N. J., Nelson, A. J., Verjans, J. W. H., Nicholls, S. J., & Psaltis, P. J. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-1 · Cited by 14
Ijioma, S. N., Emmanuel, O., Nosiri, C. I., & Ugbogu, E. A. (2020) · Scientific African · doi:10.1016/j.sciaf.2020.e00681 · Cited by 24
Kolefer, K., Miaffo, D., & Ponka, R. (2021) · The Scientific World JOURNAL · doi:10.1155/2021/1502230 · Cited by 13
Mohammed, G. F., Al‐Dhubaibi, M. S., Bahaj, S. S., & AbdElneam, A. I. (2023) · Health Science Reports · doi:10.1002/hsr2.1322 · Cited by 12
Ota, T., Ishii, H., Suzuki, S., Tanaka, A., Shibata, Y., Tatami, Y., Harata, S., Shimbo, Y., Takayama, Y., Kawamura, Y., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.11.043 · Cited by 11
Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients
Shin, S., & Lee, S. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s71559 · Cited by 11
Putative Role of Endothelial Lipase in Dialysis Patients with Hypoalbuminemia and Inflammation
Fujii, H., Fukuda, A., Tanaka, M., Kojima, Y., Ishida, T., Hirata, K., & Fukagawa, M. (2008) · American Journal of Nephrology · doi:10.1159/000144025 · Cited by 11
Ouwens, M., Nauta, J. J. P., Ansquer, J.-C., & Driessen, S. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1098597 · Cited by 11
Ugwu, C. E., Olajide, J. E., Alumana, E. O., & Ezeanyika, L. U. S. (2011) · African Journal of Biochemistry Research · doi:10.5897/ajbr.9000061 · Cited by 13
Kakuda, H., Matoba, M., Nakatoh, H., Nagao, S., & Takekoshi, N. (2014) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2014.882015 · Cited by 12
Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome
Koncsos, P., Fülöp, P., Juhász, I., Bíró, K., Márk, L., Simonyi, G., & Paragh, G. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-1035-4 · Cited by 11
Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee
Wang, W., Blackett, P. R., Khan, S. H., & Lee, E. T. (2017) · Journal of Lipids · doi:10.1155/2017/8236325 · Cited by 12
Dhungana, S. P., Mahato, A. K., Ghimire, R., & Shreewastav, R. K. (2020) · Journal of Nepal Medical Association · doi:10.31729/jnma.4765 · Cited by 20
Mahamad, A. T., Miaffo, D., Kamani, S. L. P., Mahamat, O., Kamanyi, A., & Ngnokam, S. L. W. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00687-x · Cited by 13
Hong, B. V., Zhu, C., Wong, M., Sacchi, R., Rhodes, C. H., Kang, J. W., Arnold, C. D., Adu‐Afarwuah, S., Lartey, A. A., Oaks, B. M., et al. (2021) · ACS Omega · doi:10.1021/acsomega.1c04811 · Cited by 13
Lipid lowering therapy in type 2 diabetes
Föger, B. (2011) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-011-0908-4 · Cited by 11
“Not unexpectedly, it is also a good predictor of cardiovascular risk in coronary patients on standard-intensity [38] and high-intensity [39] statins.”
Novel Therapies for Increasing Serum Levels of HDL
Toth, P. P. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.012 · Cited by 12
Coca, A., Cea‐Calvo, L., Lozano, J. V., Inaraja, V., Fernández, C., Navarro, J., Bonet, Á., & Redón, J. (2009) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(09)73268-2 · Cited by 11
The Relationships Between Self-Rated Health and Serum Lipids Across Time
Shirom, A., Toker, S., Melamed, S., & Shapira, I. (2011) · International Journal of Behavioral Medicine · doi:10.1007/s12529-011-9144-y · Cited by 11
“Following this rationale, in the current study we focus on three types of serum lipids: (a) high-density lipoprotein cholesterol (HDL-C), high values of which are considered to be protective against CVD [ 1 ]; (b) low-density lipoprotein cholesterol (LDL-C), a major risk factor in the etiology of cardiovascular diseas…”
MethodThe lipid triad, or how to reduce residual cardiovascular risk?
Girard-Mauduit, S. (2010) · Annales d Endocrinologie · doi:10.1016/j.ando.2010.02.001 · Cited by 18
Fukuda, Y., Miura, S., Tsuchiya, Y., Sumi-Inoue, Y., Kubota, K., Takamiya, Y., Kuwano, T., Ohishi, H., Ike, A., Mori, K., et al. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.01.088 · Cited by 11
“In the TNT trial, even with the intensive lowering of LDL-C below 70 mg/dl, HDL-C levels predicted major cardiovascular events [9].”
BackgroundThe association of dyslipidemia with erythrocyte aggregation
Gyawali, P., Richards, R. S., Bwititi, P., & Nwose, E. U. (2015) · Clinical Lipidology · doi:10.2217/clp.15.3 · Cited by 12
The 6th Annual World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2009) · Diabetes Care · doi:10.2337/dc09-zb09 · Cited by 13
Dong, J., Huang, A., Zhang, Z., Yang, X., Sun, J., & Zhang, W. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1642243 · Cited by 10
“Likewise, elevated HDL-C levels have consistently been linked to a lower risk of cardiovascular events, even among individuals with LDL-C levels below 70 mg/dL (37, 38).”
Lipids profile in children and adolescents with β-thalassemia major
Jabbar, H. K., Hassan, M. K., & Al-Naama, L. M. (2022) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2022.09.1277 · Cited by 18
Jarvie, J. L., Johnson, C. E., Wang, Y., Aslam, F., Athanasopoulos, L. V., Pollin, I. S., & Foody, J. M. (2010) · Journal of Women s Health · doi:10.1089/jwh.2010.2036 · Cited by 10
Nicholls, S. J., Uno, K., Tuzcu, E. M., & Nissen, S. E. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0125-4 · Cited by 9
“This relationship is observed regardless of levels of LDL cholesterol or triglyceride [ 7 ].”
BackgroundYiu, K., Cheung, B. M. Y., & Tse, H. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003623223 · Cited by 11
Residual Vascular Risk in T2DM: The Next Frontier
Michel, P., Sylvie, A., & Michel, F. (2011) · InTech eBooks · doi:10.5772/22716 · Cited by 10
Elbaz, M., Faccini, J., Bongard, V., Ingueneau, C., Taraszkiewicz, D., Perret, B., Ferrières, J., Ruidavets, J., & Vindis, C. (2016) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2016.04.007 · Cited by 10
Lipids and Lipoproteins in Risk Prediction
Hadjiphilippou, S., & Ray, K. K. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.002 · Cited by 12
Dysfunctional high-density lipoprotein and atherogenesis
Kosmas, C. E., Silverio, D., Sourlas, A., Montan, P. D., & Guzman, E. (2019) · Vessel Plus · doi:10.20517/2574-1209.2018.79 · Cited by 10
Atherogenic indices in pseudoexfoliation syndrome
Mirza, E. (2019) · Eye · doi:10.1038/s41433-019-0506-z · Cited by 12
Dod, R., Rajendran, A., Kathrotia, M., Clarke, A., & Dodani, S. (2022) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-022-01306-6 · Cited by 13
HDL as Bidirectional Lipid Vectors: Time for New Paradigms
Luna‐Luna, M., Niesor, E. J., & Pérez-Méndez, O. A. (2022) · Biomedicines · doi:10.3390/biomedicines10051180 · Cited by 11
Afiaenyi, I. C., Ngwu, E. K., Okafor, A. M.-A., & Ayogu, R. N. B. (2023) · Nutrition and Health · doi:10.1177/02601060231176873 · Cited by 10
Ning, L., He, C., Lu, C., Huang, W., Zeng, T., & Su, Q. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28154 · Cited by 12
“HDL cholesterol [56,57] is often referred to as "good" cholesterol due to its role in removing excess cholesterol from the bloodstream, and a lower HDL cholesterol level is associated with an increased risk of cardiovascular disease.”
BackgroundRamachandran, S., Abbas, A., Saraf, S., Raju, J., Jewkes, C., & Jones, A. F. (2012) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2011.0112 · Cited by 10
Veiga, M. F., Rodrigues, I. F. S., Cardinalli-Neto, A., Otaviano, A. P., da Rocha, B. F., & Bestetti, R. B. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.01.090 · Cited by 10
Wang, F., & Ye, P. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-163 · Cited by 10
The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results
Santos‐Gallego, C. G., Torres, F., & Badimón, J. J. (2011) · Clinical Lipidology · doi:10.2217/clp.10.90 · Cited by 11
Yun, K. H., Shin, S.-N., Ko, J. S., Rhee, S. J., Kim, N., Oh, S. K., & Jeong, J. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.07.008 · Cited by 11
“However, there is circumstantial evidence that statin-induced igh-density lipoprotein cholesterol (HDL-C) increase may also ontribute to the benefit [6,7].”
BackgroundDysfunctional HDL and Cardiovascular Disease Risk in Individuals with Diabetic Dyslipidemia
Elboudwarej, O., Hojjat, H., & Safarpoor, S. (2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s4-001 · Cited by 10
Соколенко, В. Л., & Соколенко, С. В. (2017) · Regulatory Mechanisms in Biosystems · doi:10.15421/021736 · Cited by 10
Wang, X., Lin, X., Xu, X., Li, W., Hao, L., Liu, C., Zhao, D., & Cheng, M. (2017) · Molecules · doi:10.3390/molecules22111925 · Cited by 10
Underperforming doctors in general practice: a survey of referrals to UK Deaneries.
Bahrami, J., & Evans, A. (2001) · Europe PMC (PubMed Central) · Cited by 10
Wang, Y., Wei, C., Song, Q., Liu, J., Cheng, Y., Li, Y., Wu, B., & Liu, M. (2019) · Current Neurovascular Research · doi:10.2174/1567202616666190619151914 · Cited by 11
Lee, H. Y., Lee, D. H., Lee, B. K., Jeung, K. W., Jung, Y. H., Park, J. S., Min, J. H., & Min, Y. I. (2019) · Resuscitation · doi:10.1016/j.resuscitation.2019.10.005 · Cited by 10
Ascaso, J. F., Millán, J., Hernández‐Mijares, A., Blasco, M., Brea, Á., Díaz, Á., Pedro‐Botet, J., & Pintó, X. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2020.05.002 · Cited by 12
“…de episodios cardiovas-culares graves del 21% y de accidentes coronarios en un 23% Un hecho relevante es que el tratamiento con estati-nas durante 10 a˜nos en sujetos con bajo RCV se relacionó 20,21 epi-sodios cardiovasculares, de forma similar a lo observado con la reducción del cLDL 22 .”
BackgroundVoisin, M., Shrestha, E., Rollet, C., Nikain, C. A., Josefs, T., Mahé, M., Barrett, T. J., Chang, H. R., Ruoff, R., Schneider, J. A., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01925-5 · Cited by 10
Ghanavati, M., Parsa, S. A., & Nasrollahzadeh, J. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14431 · Cited by 13
Yan, Y.-Q., Chen, J., & Huang, Y. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s313006 · Cited by 11
Atherogenic indices in non-arteritic ischemic optic neuropathy
Koçak, N., Turunç, M., Bayrambas, M., Eraydın, B., & Güngör, İ. (2021) · International Journal of Ophthalmology · doi:10.18240/ijo.2021.07.12 · Cited by 11
Clinical Equivalence of Proprietary and Generic Atorvastatin in Lipid Clinic Patients
Rahalkar, A. R., Ban, M. R., & Hegele, R. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.05.010 · Cited by 10
de Araújo, A. B., Chiu, G. R., Christian, J. B., Kim, H. Y., Evans, W. J., & Clark, R. V. (2013) · Clinical Endocrinology · doi:10.1111/cen.12212 · Cited by 10
Population-Based Resequencing of LIPG and ZNF202 Genes in Subjects with Extreme HDL Levels
Razzaghi, H., Santorico, S. A., & Kamboh, M. I. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00089 · Cited by 10
Managing Mixed Dyslipidemia in Special Populations
Miller, M. J. (2009) · Preventive Cardiology · doi:10.1111/j.1751-7141.2009.00057.x · Cited by 11
O’Halloran, J. A., Satchell, C. S., & Mallon, P. W. G. (2013) · Future Virology · doi:10.2217/fvl.13.87 · Cited by 16
Aroused versus calm positive affects as predictors of lipids.
Shirom, A., Melamed, S., Berliner, S. A., & Shapira, I. (2009) · Health Psychology · doi:10.1037/a0015988 · Cited by 11
“HDL-C was found to be a strong predictor of CVD in many large-scale studies, sometimes a more potent predictor for CVD than was the level of LDL-C (Barter et al., 2007); therefore our findings could have clinical relevance, also because male gender is a risk factor for hypercholesterolemia (Bhatnagar et al.”
Result
Metadata
- Authors
- Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C.
- Affiliations
- The Heart Research Institute (AU)
- Cornell University (US)
- SUNY Downstate Health Sciences University (US)
- Pfizer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Alabama (US)
- Institut Pasteur de Lille (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-27
- Volume
- 357
- Issue
- 13
- Pages
- 1301-1310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158057499
- Cited by
- 1,610
- References
- 24
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 34 · 2023: 48 · 2022: 36 · 2021: 51 · 2020: 79 · 2019: 72 · 2018: 59 · 2017: 75 · 2016: 90 · 2015: 106 · 2014: 128 · 2013: 126 · 2012: 130
- FWCI
- 113.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HDL cholesterol, LDL cholesterol, very low LDL cholesterol, major cardiovascular events, statin therapy, cardiovascular risk prediction, coronary artery disease, myocardial infarction, stroke, low HDL cholesterol
- MeSH terms
- Atorvastatin, Adult, Aged, Anticholesteremic Agents, Apolipoproteins, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Risk, Multivariate Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.